Abstract
The identification and management of a pituitary tumor is straightforward once the potential diagnosis is entertained. The greatest difficulty in clinical medicine is the delay in diagnosis because of a nonspecific clinical feature, such as headache, which is attributed to “stress” or a migraine syndrome. Similarly, nonspecific complaints of decreased energy, libido, and weight gain may be attributed to depression or aging. Thus, the greatest challenge to the physician is to entertain the possibility that a patient’s symptoms may be related to a pituitary tumor and/or pituitary dysfunction. Because of excellent imaging technology, magnetic resonance imaging (MRI), many patients are now found to have a pituitary lesion incidentally—the study was obtained to “rule out” intracranial pathology because of trauma or headaches. Once a pituitary tumor is considered or found, it is then necessary to determine the type of tumor (secretory, nonsecretory), pituitary function (hypo- and hyperfunction), the need for hormone replacement, and the status of the visual system before recommending appropriate therapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Moltich ME, Russell EJ. The pituitary “incidentaloma.” Ann Intern Med 1990;112:925–931.
Burrow GN, Wortzman G, Rewcastle NB, Holgate RC, Kovacs K. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. N Engl J Med 1981;304:156–158.
Chong BW, Kucharczyk W, Singer W, George S. Pituitary gland MR: A comparative study of healthy volunteers and patients with microadenomas. AJNR Am J Neuroradiol 1994;15:675–679.
Elster AD. Modern imaging of the pituitary. Radiology 1993; 187:1–14.
Donovan LE, Corenblum B. The natural history of the pituitary incidentaloma. Arch Intern Med 1995;155:181–183.
Oldfield EH, Doppman JL, Nieman LK, Chrousos GP, Miller DL, Katz DA, et al. Petrosal sinus sampling with and without corticotro-pin-releasing hormone for the differential diagnosis of Cushing’s Syndrome. N Engl J Med 1991;325:897–905.
Yanovski JA, Cutler GB, Doppman JL, Miller DL, Chrousos GP, Oldfield EH, et al. J Clin Endocrinol Metab 1993;77:503–509.
Ebersold MJ, Quast LM, Laws ER, Scheithauer B, Randall RV. Long-term results in transsphenoidal removal of nonfunctioning pituitary adenomas. J Neurosurg 1986;64:713–719.
Kleinberg DL, Boyd AE, Wardlaw S, et al. Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone. N Engl J Med 1983; 309:704–709.
Vance ML, Lipper M, Klibanski A, et al. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205–502. Ann Intern Med 1990;112: 668–673.
Ciccarelli E, Giusti M, Miola C, et al. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. J Clin Endocrinol Metab 1989; 69:725–728.
Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group [see comments]. N Engl J Med 1994; 331:904–909.
Biller BMK, Molitch ME, Vance ML, et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996; 81:2338–2343.
Sassolas G, Fossati P, Chanson P, et al. Experience of a six-month treatment with sandostatin at increasing doses in acromegaly. Horm Res 1989;31:51–54.
Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Arch Int Med 1991; 151:1573–1578.
Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long term octreotide therapy of acromegaly-results of a multicenter trial in 103 patients. J Clin Endocrinol Metab 1995; 80:2768–2775.
Reubi JC, Landolt AM. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. J Clin Endocrinol Metab 1989;68:844–850.
Ezzat S, Snyder PJ, Young WF, et al. Octreotide treatment of acromegaly: a randomized, multicenter study. Ann Intern Med 1992; 117:711–718.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Vance, M.L. (2001). Diagnosis, Management, and Prognosis of Pituitary Tumors. In: Thapar, K., Kovacs, K., Scheithauer, B.W., Lloyd, R.V. (eds) Diagnosis and Management of Pituitary Tumors. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-217-3_9
Download citation
DOI: https://doi.org/10.1007/978-1-59259-217-3_9
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4684-9693-2
Online ISBN: 978-1-59259-217-3
eBook Packages: Springer Book Archive